 |
 |
 |
 |
 |
 |
 |
 |
Potentia is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
The safety of Potentia's POT-4, a small cyclic synthetic peptide, was confirmed by the ASaP Phase I clinical trial conducted in wet AMD patients at multiple sites across the United States.
The ASaP trial was recently completed and POT-4 was well tolerated in all patients at all doses.
more info on POT-4 »
- May 2009 Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
more » - November 2008 Potentia Pharmaceuticals Appoint Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
more » - November 2008 Potentia Pharmaceuticals’ Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
more »
